Clinical trials: Isolated Limb Perfusion
Neoplasms
A Study of ADH-1 in Combination With Normothermic Isolated Limb Infusion of Melphalan
N-cadherin, a protein involved in blood vessel cell binding and on the surface of many tumor cells, is increased as cancer progresses. ADH-1 blocks N-cadherin.
- Trial name
- NCT00421811
- Testing
- ADH-1, melphalan
- Where
- 7 sites in United States
- Volunteers
- 56 people
- Sponsor
- Adherex Technologies, Inc.
Peripheral Arterial Disease
Augmentation of Limb Perfusion With Contrast Ultrasound
Our laboratory has discovered that ultrasound (US) imaging together with clinically approved microbubble ultrasound contrast agents can augment limb tissue perfusion.
- Trial name
- NCT03195556
- Testing
- Ultrasound
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Oregon Health and Science University
In-transit Metastases Melanoma Stage IIIB and IIIC
Trial of Ipilimumab After Isolated Limb Perfusion, in Patients With Metastases Melanoma
Isolated limb perfusion (ILP) results in good response rates for locally advanced melanoma (stage IIIB and IIIC, AJCC 2009). Outcome is influenced by stage of disease, reflecting the aggressiveness of the melanoma.
- Trial name
- ILP+/-IPI (NCT02094391)
- Testing
- Ipilimumab
- Where
- France
- Volunteers
- 4 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Patients With Intransit Stage III/IV Melanoma
Phase 1 Dose-finding Study of L19TNFα Plus Melphalan Using Isolated Inferior Limb Perfusion (ILP) in Subjects With Intransit Stage III/IV Melanoma
In this study the recombinant human fusion protein L19TNFα will be associated in ILP with the standard treatment with melphalan 10mg/l limb volume in subjects affected by stage III/IV limb melanoma.
- Trial name
- NCT01213732
- Testing
- Isolated inferior limb perfusion
- Where
- 2 sites in Italy
- Volunteers
- 19 people
- Sponsor
- Philogen S.p.A.
Metastatic Melanoma
Isolated Limb Perfusion of Melphalan for Melanoma and Sarcoma Treatment
In-transit metastases occur in approximately 3% of melanoma patients, can be very symptomatic and the survival in this group may be prolonged. In-transit melanoma metastases are often confined to a limb.
- Trial name
- ILI (NCT01920516)
- Testing
- Melphalan
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- International Group of Endovascular Oncology
Polyneuropathies, Regional Blood Flow
Comparative Effectiveness of Nursing Interventions: Using Buerger-Allen Exercises Versus Mechanical Compression Therapy on Lower Limb Perfusion and Peripheral Neuropathy Among Patients Undergoing Chemotherapy.
Chemotherapy-induced peripheral neuropathy (CIPN) and impaired lower-limb circulation are common adverse effects that can compromise patients' mobility, comfort, balance, functional independence, and quality of life and may…
- Conditions
- Polyneuropathies, Regional Blood Flow, Lower Extremity
- Trial name
- RCT (NCT07842237)
- Testing
- mechanical compression therapy, Exercises
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Damanhour University
Recurrent Melanoma, Stage III Melanoma
Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Locally Advanced Melanoma of the Arm or Leg
Randomized phase III trial to compare the effectiveness of hyperthermic isolated limb perfusion of melphalan with or without tumor necrosis factor in treating patients who have locally advanced melanoma of the arm or leg.
- Trial name
- NCT00003789
- Testing
- isolated limb perfusion, melphalan, recombinant tumor necrosis factor family protein
- Where
- United States
- Volunteers
- 216 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma (Skin), Sarcoma
Isolated Limb Infusion of Chemotherapy in Treating Patients With Melanoma or Soft Tissue Sarcoma of the Arm or Leg That Cannot Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Infusing chemotherapy to the tumor area only may kill more tumor cells and cause less damage to healthy…
- Trial name
- NCT00004250
- Testing
- dactinomycin, isolated limb perfusion, melphalan
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Diabetic Peripheral Neuropathic Pain, Balance Changes
Buerger Exercises With Whole Body Vibration in Diabetic Peripheral Neuropathy
The goal of this clinical trial is to determine if a combined intervention of Buerger exercises and whole-body vibration therapy can improve pain, circulation, and balance in adults with diabetic peripheral neuropathy.
- Conditions
- Diabetic Peripheral Neuropathic Pain, Balance Changes, Ankle Brachial Index
- Trial name
- NCT06737861
- Testing
- Group A, Group B
- Where
- Pakistan
- Volunteers
- 64 people
- Sponsor
- Riphah International University
Diabetes, Infection
Technology That Permits Focal Dose of Antibiotics to be Delivered to Lower Limb(s) of Diabetic Patients
The use of the Percutaneous Isolated Limb Procedure (PILP) which enables the use of existing antibiotic therapies in a more targeted and concentrated fashion in patients with diabetes who have a significant lower limb infection…
- Trial name
- NCT02158442
- Testing
- Percutaneous Isolated Limb Perfusion (PILP) delivery, Timentin
- Where
- Australia
- Volunteers
- 15 people
- Sponsor
- Osprey Medical, Inc
Type 2 Diabetes, Peripheral Arterial Disease
Liraglutide and Peripheral Artery Disease
STARDUST is an open-label, two-arm randomized controlled trial, aimed at evaluating the effects of liraglutide on peripheral perfusion, as compared with the aggressive treatment of cardio-metabolic risk factors, in people with…
- Trial name
- STARDUST (NCT04881110)
- Testing
- Liraglutide, Control
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- University of Campania Luigi Vanvitelli
Melanoma
Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity
The purpose of this study is to see the effect of adding a systemic study drug, Ipilimumab, to two standard chemotherapy drugs, Melphalan and Dactinomycin.
- Trial name
- NCT01323517
- Testing
- Ipilimumab, Melphalan and Dactinomycin
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Bleeding
Assessment of Limb Perfusion During Junctional Tourniquet
The goal of this study is to use contrast enhanced ultrasound to determine the degree to which flow is reduced during application of a junctional tourniquet (JT).
- Trial name
- NCT02092415
- Testing
- Application of a Junctional Tourniquet
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Oregon Health and Science University
Melanoma, Sarcoma
A Randomized Controlled Study Comparing Priming Solution Containing Crystalloid or Packed Red Blood Cells in Patients Treated With Isolated Limb Perfusion.
The primary aim of this study is to investigate the possibility to replace an erythrocyte based prime solution with a crystalloid based prime solution while maintaining metabolic function.
- Trial name
- ILP-Prime (NCT03073304)
- Testing
- Crystalloid based prime solution, Erythrocyte based prime solution
- Where
- Sweden
- Volunteers
- 18 people
- Sponsor
- Vastra Gotaland Region
Melanoma
Evaluate Safety/Tolerability Intra-Arterial Temozolomide in Patients w/Extremity Melanoma by Isolated Limb Infusion
The purpose of this study is to determine the safety profile of intra-arterial temozolomide administration during Isolated Limb Infusion (ILI) by defining the dose limiting toxicities associated with this treatment.
- Trial name
- NCT01127594
- Testing
- Temozolomide
- Where
- 3 sites in United States
- Volunteers
- 29 people
- Sponsor
- Douglas Tyler
Stage IVB Adult Soft Tissue Sarcoma, Stage IIB Adult Soft Tissue Sarcoma
Isolated Limb Perfusion of Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Soft Tissue Sarcoma of the Arm or Leg
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Infusing melphalan directly to the tumor may kill more tumor cells and cause less damage to healthy tissues.
- Conditions
- Stage IVB Adult Soft Tissue Sarcoma, Stage IIB Adult Soft Tissue Sarcoma, Stage IIC Adult Soft Tissue Sarcoma, Recurrent Adult Soft Tissue Sarcoma
- Trial name
- NCT00019968
- Testing
- melphalan, tumor necrosis factor
- Sponsor
- National Institutes of Health Clinical Center (CC)
Peripheral Arterial Disease, Peripheral Vascular Diseases
The Effects of Oral Inorganic Nitrate Supplementation on Lower Limb Perfusion During Exercise in Patients With PAD
Peripheral arterial disease (PAD) is a highly prevalent and costly condition. Intermittent claudication (IC), defined as ischemic leg pain that occurs with walking, results in functional impairment, reduced daily physical…
- Trial name
- NCT05036213
- Testing
- BEET IT - Concentrate Beet root juice, BEET IT - Concentrate Beet root juice (nitrate depleted)
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Virginia
Melanoma
EF5 in Melanoma Patients
The purpose of this pilot study is to determine the prevalence of markers of chronic and cycling hypoxia and reactive species stress (oxidative and nitrosative) in the melanoma tumor microenvironment.
- Trial name
- NCT01752257
- Testing
- EF5 Hypoxia
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Douglas Tyler
Melanoma, In-Transit Metastasis
Evaluating the Effect of Nivolumab for Patients With In-transit Metastases Treated With Isolated Limb Perfusion
To evaluate safety and the effect of isolated limb perfusion together with nivolumab as a way to increase efficacy and give further insights in early immunological mechanisms.
- Trial name
- NivoILP (NCT03685890)
- Testing
- Nivolumab, Isolated limb perfusion (ILP)
- Where
- 4 sites in Netherlands, Sweden
- Volunteers
- 74 people
- Sponsor
- Vastra Gotaland Region
Melanoma, Sarcoma
Pilot Study of a Double Isolation Perfusion Schedule Using Melphalan Alone for Intransit Melanoma or Unresectable Sarcoma of the Extremity
Hyperthermic isolated limb perfusion with melphalan alone is administered as a double perfusion schedule. These two isolates limb perfusions with melphalan are treated 3-6 weeks apart.
- Trial name
- NCT00001577
- Testing
- double isolated limb perfusion with melphalan alone
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)